E

Exelixis
D

EXEL

46.150
USD
1.84
(4.15%)
مغلق
حجم التداول
312,357
الربح لكل سهم
2
العائد الربحي
-
P/E
21
حجم السوق
12,585,487,122
أصول ذات صلة
ABBV
ABBV
-1.530
(-0.80%)
189.200 USD
AZN
AZN
-1.530
(-2.15%)
69.590 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
C
CRVS
-0.03500
(-0.88%)
3.95500 USD
INCY
INCY
0.300
(0.44%)
68.470 USD
MRK
MRK
-1.370
(-1.66%)
81.010 USD
N
NKTR
-0.740
(-2.90%)
24.775 USD
PFE
PFE
0.110
(0.43%)
25.440 USD
المزيد
الأخبار المقالات

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.